[go: up one dir, main page]

MX2022012424A - Tratamiento del sindrome del cromosoma x fragil con canabidiol. - Google Patents

Tratamiento del sindrome del cromosoma x fragil con canabidiol.

Info

Publication number
MX2022012424A
MX2022012424A MX2022012424A MX2022012424A MX2022012424A MX 2022012424 A MX2022012424 A MX 2022012424A MX 2022012424 A MX2022012424 A MX 2022012424A MX 2022012424 A MX2022012424 A MX 2022012424A MX 2022012424 A MX2022012424 A MX 2022012424A
Authority
MX
Mexico
Prior art keywords
fragile
syndrome
cannabidiol
treatment
subject
Prior art date
Application number
MX2022012424A
Other languages
English (en)
Inventor
John Messenheimer
Nancy Tich
Donna Gutterman
Terri Sebree
Marcel Bonn-Miller
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2022012424A publication Critical patent/MX2022012424A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente tecnología se refiere a un método de tratamiento de uno o más síntomas de conducta del síndrome del cromosoma X frágil en un sujeto, mediante la administración transdérmica de una cantidad eficaz de canabidiol (CBD) al sujeto, con lo que son tratados en el sujeto uno o más síntomas de conducta del síndrome del cromosoma X frágil.
MX2022012424A 2017-09-28 2020-07-13 Tratamiento del sindrome del cromosoma x fragil con canabidiol. MX2022012424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762564834P 2017-09-28 2017-09-28
US201862632532P 2018-02-20 2018-02-20

Publications (1)

Publication Number Publication Date
MX2022012424A true MX2022012424A (es) 2022-11-30

Family

ID=63878731

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003606A MX2020003606A (es) 2017-09-28 2018-09-27 Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2022012424A MX2022012424A (es) 2017-09-28 2020-07-13 Tratamiento del sindrome del cromosoma x fragil con canabidiol.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020003606A MX2020003606A (es) 2017-09-28 2018-09-27 Tratamiento del sindrome del cromosoma x fragil con canabidiol.

Country Status (22)

Country Link
US (13) US10213390B1 (es)
EP (3) EP4414030A3 (es)
JP (5) JP7210564B2 (es)
KR (2) KR20220045070A (es)
AU (2) AU2018343256B2 (es)
BR (1) BR112020005918A2 (es)
CA (1) CA3077330A1 (es)
CY (1) CY1125071T1 (es)
DK (1) DK3687513T3 (es)
ES (2) ES2992838T3 (es)
HR (1) HRP20220277T1 (es)
HU (1) HUE058102T2 (es)
IL (1) IL273495A (es)
JO (1) JOP20200082A1 (es)
LT (1) LT3687513T (es)
MX (2) MX2020003606A (es)
PL (1) PL3687513T3 (es)
PT (1) PT3687513T (es)
RS (1) RS62969B1 (es)
SI (1) SI3687513T1 (es)
SM (1) SMT202200093T1 (es)
WO (1) WO2019064234A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992838T3 (en) 2017-09-28 2024-12-18 Harmony Biosciences Man Inc Treatment of irritability in autism spectrum disorder with cannabidiol
KR20210104084A (ko) 2018-12-14 2021-08-24 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
EP4031119B1 (en) * 2019-09-17 2025-12-17 Harmony Biosciences Management, Inc. Transdermal treatment of behavioral impairment in developmental and epileptic encephalopathy with cbd
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
MX2022004257A (es) 2019-10-11 2022-05-26 Pike Therapeutics Inc Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
GB2589306A (en) * 2019-10-25 2021-06-02 Gw Res Ltd Use of cannabidiol preparations in the treatment of fragile X syndrome
JP7412583B2 (ja) 2020-02-07 2024-01-12 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物
EP4157236A1 (en) * 2020-05-26 2023-04-05 Zynerba Pharmaceuticals, Inc. Treatment of autism spectrum disorder with cannabidiol
BR112022026044A2 (pt) * 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
IL303388A (en) * 2020-12-03 2023-08-01 Zynerba Pharmaceuticals Inc Treatment of refractory convulsions
CN116782891A (zh) * 2020-12-03 2023-09-19 Zyne制药公司 大麻二酚对难治性癫痫发作的治疗
JP2024536581A (ja) * 2021-10-22 2024-10-04 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 中等度から重度の不安及び／又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
FI20020333A0 (fi) 2002-02-20 2002-02-20 Tomi Jaervinen Metyloidun syklodekstriinin uudet kompleksit
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
EP2424525A1 (en) 2009-04-28 2012-03-07 AllTranz Inc. Formulations of cannabidiol and methods of using the same
PT2473475T (pt) 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
MX381719B (es) 2013-01-08 2025-03-12 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Compuestos cbd fluorados, composiciones y usos de los mismos.
US9943491B2 (en) 2013-10-29 2018-04-17 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20170224634A1 (en) 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
AU2015266897B2 (en) 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
ES2877361T3 (es) 2014-06-27 2021-11-16 Farm To Farma Inc Formulaciones de cannabinoides bucales y sublinguales y método para hacer las mismas
US20160000843A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
US20190060300A1 (en) 2016-03-04 2019-02-28 Sharon Anavi-Goffer Self-Emulsifying Compositions of CB2 Receptor Modulators
PL3429580T3 (pl) 2016-03-16 2025-09-22 Buzzelet Development And Technologies Ltd Kompozycja kannabinoidowa wzbogacona terpenami
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en) 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
EP3445179A4 (en) 2016-04-19 2020-07-22 Canna-B Cure Ltd ENZYMATICALLY TREATED THERAPEUTIC COMPOSITION ENRICHED IN CANNABIS
EP3478270A4 (en) 2016-06-02 2019-11-27 Acerus Labs, Inc. HALF-RESISTANT AND VISCOUS LIQUID, NADAL FORMULATIONS OF CANNABINOIDS
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN107126411A (zh) * 2017-03-22 2017-09-05 哈尔滨惠美佳生物科技有限公司 具有缓解神经性头痛作用的大麻二酚凝胶及其制备方法
WO2019034985A1 (en) 2017-08-14 2019-02-21 Zynerba Pharmaceuticals, Inc. METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
JP2021500312A (ja) 2017-09-15 2021-01-07 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 自閉症の治療のための組成物および方法
US20230059709A1 (en) 2017-09-28 2023-02-23 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome with cannabidiol
ES2992838T3 (en) 2017-09-28 2024-12-18 Harmony Biosciences Man Inc Treatment of irritability in autism spectrum disorder with cannabidiol
US11857530B2 (en) 2017-10-30 2024-01-02 Endocanna Health, Inc. Cannabinoid formulations
CA3101334A1 (en) 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
KR20210104084A (ko) 2018-12-14 2021-08-24 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
US20230000793A1 (en) 2018-12-14 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000792A1 (en) 2018-12-14 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
EP4157236A1 (en) 2020-05-26 2023-04-05 Zynerba Pharmaceuticals, Inc. Treatment of autism spectrum disorder with cannabidiol
BR112022026044A2 (pt) 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
GB2597322A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
JP2024536581A (ja) 2021-10-22 2024-10-04 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 中等度から重度の不安及び／又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療

Also Published As

Publication number Publication date
US20200214995A1 (en) 2020-07-09
US20190167605A1 (en) 2019-06-06
EP3687513B1 (en) 2021-12-15
US20230364028A1 (en) 2023-11-16
US10471022B2 (en) 2019-11-12
RS62969B1 (sr) 2022-03-31
BR112020005918A2 (pt) 2020-10-06
JP2025106310A (ja) 2025-07-15
CY1125071T1 (el) 2023-06-09
US20190262280A1 (en) 2019-08-29
US20220096396A1 (en) 2022-03-31
US20200360299A1 (en) 2020-11-19
JOP20200082A1 (ar) 2020-04-30
JP2025061375A (ja) 2025-04-10
ES2907325T3 (es) 2022-04-22
ES2992838T3 (en) 2024-12-18
US20250134833A1 (en) 2025-05-01
US10758497B2 (en) 2020-09-01
CA3077330A1 (en) 2019-04-04
US12213951B2 (en) 2025-02-04
EP4414030A2 (en) 2024-08-14
JP2022064988A (ja) 2022-04-26
US12226373B2 (en) 2025-02-18
JP2020535190A (ja) 2020-12-03
AU2024220039A1 (en) 2024-10-17
PT3687513T (pt) 2022-03-01
HUE058102T2 (hu) 2022-07-28
US20230000790A1 (en) 2023-01-05
AU2018343256A1 (en) 2020-04-02
HRP20220277T1 (hr) 2022-05-13
MX2020003606A (es) 2020-10-28
EP3967301B1 (en) 2024-06-19
US10568848B2 (en) 2020-02-25
US20250134832A1 (en) 2025-05-01
AU2018343256B2 (en) 2024-09-19
SI3687513T1 (sl) 2022-04-29
KR20200058513A (ko) 2020-05-27
JP7210564B2 (ja) 2023-01-23
US20230414533A1 (en) 2023-12-28
US20200030255A1 (en) 2020-01-30
US20190117588A1 (en) 2019-04-25
LT3687513T (lt) 2022-03-10
PL3687513T3 (pl) 2022-04-19
EP4414030A3 (en) 2024-11-20
IL273495A (en) 2020-05-31
US11779549B2 (en) 2023-10-10
JP2023040166A (ja) 2023-03-22
US10213390B1 (en) 2019-02-26
SMT202200093T1 (it) 2022-05-12
US11458110B2 (en) 2022-10-04
KR102786277B1 (ko) 2025-03-26
EP3967301A1 (en) 2022-03-16
US10314792B2 (en) 2019-06-11
EP3687513A1 (en) 2020-08-05
KR20220045070A (ko) 2022-04-12
DK3687513T3 (da) 2022-03-07
WO2019064234A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
EA201690206A1 (ru) Терапевтически активные соединения и способы их применения
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
MX2017004580A (es) Combinaciones de auristatina sinergica.
ZA202005388B (en) Methods of treating ulcerative colitis
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
MX2015010191A (es) Metodos para tratar infecciones microbianas, incluyendo mastitis.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
JOP20220338A1 (ar) علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
BR112016012248A2 (pt) método de tratamento de nefropatia
BR112019008241A2 (pt) tratamento do prurigo nodular
EA201690445A1 (ru) Лечение рака
EA201690446A1 (ru) Лечение множественной миеломы
BR112015023260A2 (pt) método de tratamento de grão com ozônio
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
BR112016014099A2 (pt) método de tratamento de feridas